Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibuprofen/sodium cromoglicate- AZTherapies

Next Previous
Drug Profile

Ibuprofen/sodium cromoglicate- AZTherapies

Alternative Names: ALZT OP1; ALZT-OP1a + ALZT-OP1b; Ibuprofen + cromolyn; Ibuprofen + sodium cromoglicate

Latest Information Update: 22 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AZTherapies
  • Class Amines; Analgesics; Antiallergics; Antiasthmatics; Antidementias; Antipyretics; Antirheumatics; Antitussives; Benzopyrans; Chromones; Neuroprotectants; Nonsteroidal anti-inflammatories; Nootropics; Phenylpropionates; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 22 Apr 2022 Phase-III development is ongoing in the US, Australia, Canada, Bulgaria, Czech Republic, Poland, and Hungary
  • 18 Jan 2021 AZTherapies completes a phase I/II trial in Alzheimer's disease in USA (PO) (NCT04570644)
  • 13 Nov 2020 AZTherapies completes the phase III COGNITE trial for Alzheimer's disease (Early-stage disease) in USA, Australia, Bulgaria, Canada, Czech Republic, Hungary and Poland (PO) (NCT02547818)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top